NCT02688556View on ClinicalTrials.gov

Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

PHASE3CompletedINTERVENTIONAL
Enrollment

745

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

December 31, 2016

Conditions
Keratoconjunctivitis Sicca
Interventions
DRUG

cyclosporine

DRUG

vehicle of OTX-101

Trial Locations (3)

10028

Fifth Avenue Eye Associates, New York

41017

Cincinnati Eye Institute, Edgewood

95670

Martel Eye Medical Group, Rancho Cordova

All Listed Sponsors
lead

Sun Pharmaceutical Industries Limited

INDUSTRY

NCT02688556 - Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca | Biotech Hunter | Biotech Hunter